SCHEMBL4968463

SCHEMBL4968463

Cc1nc2cc(NC(=O)NCC3CCCCC3)ccc2o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.62
NPC1 O15118 4/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
STAT1 P42224 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ALDH1A1 P00352 1/20 0.59
HTT P42858 1/20 0.59
TP53 P04637 2/20 0.59
MAPK1 P28482 1/20 0.59
EPHX1 P07099 4/20 0.59
POLB P06746 3/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 1/20 0.59
LMNA P02545 1/20 0.57
EPHX2 P34913 3/20 0.54
ROCK2 O75116 1/20 0.48
F10 P00742 1/20 0.47
KDR P35968 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14470501 0.94 RAB9A (0.66) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL14470401 0.91 POLB (0.62) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL14470504 0.85 POLB (0.67) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL5523279 0.84 RAB9A (0.64) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL5520150 0.82 RAB9A (0.53) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL5520154 0.79 RAB9A (0.45) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL4971112 0.79 EPHX1 (0.58) RAB9ANPC1SMN1; SMN2ALDH1A1EPHX1
SCHEMBL4962140 0.78 RAB9A (0.56) RAB9ANPC1SMN1; SMN2STAT1L3MBTL1
SCHEMBL14470411 0.76 RAB9A (0.68) RAB9ANPC1SMN1; SMN2ALDH1A1EPHX1
SCHEMBL4965304 0.76 EPHX1 (0.70) NPC1EPHX1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1969051-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2008-09-17 EP disclosed
WO-2007079180-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2007-07-12 WO disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ABHD6 RAB9A 2202/4885NPC1 588/4885SMN1; SMN2 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.